Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRVS Stock Price Chart Interactive Chart >
CRVS Price/Volume Stats
|Current price||$1.01||52-week high||$9.54|
|Prev. close||$0.99||52-week low||$0.75|
|Day high||$1.06||Avg. volume||282,823|
|50-day MA||$1.11||Dividend yield||N/A|
|200-day MA||$2.54||Market Cap||47.02M|
Corvus Pharmaceuticals, Inc. (CRVS) Company Bio
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.
Most Popular Stories View All
CRVS Latest News Stream
|Loading, please wait...|
CRVS Latest Social Stream
View Full CRVS Social Stream
Latest CRVS News From Around the Web
Below are the latest news stories about Corvus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
Corvus Pharmaceuticals'' (CRVS) partner Angel Pharmaceuticals has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China. “We are excited that Angel has begun to enroll patients in its
Insiders who bought stock earlier this year lose -US$118k as Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) drops to US$112m
The recent 12% drop in Corvus Pharmaceuticals, Inc.'s ( NASDAQ:CRVS ) stock could come as a blow to insiders who...
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation
Data Presented in Poster Presentation at American Society of Hematology Annual MeetingBURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease (aGVHD) in patients receiving allogeneic hematopoietic cell transplantation (bone marrow transplant
Wall Street analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.17). Corvus Pharmaceuticals posted 
CRVS Price Returns